Table 2.
SABR and planning details.
| n = 114 | |
|---|---|
| Dose/fractionation | |
| 5x 10 Gy | 61 (53.5 %) |
| 3x 15 Gy | 15 (13.2 %) |
| 1x 24 Gy | 12 (10.5 %) |
| 5x 8 Gy | 11 (9.6 %) |
| 4x 10 Gy | 4 (3.5 %) |
| Other* | 11 (9.7 %) |
| Single fraction 16–24 Gy | 15 (13.2 %) |
| BED10 ≥ 80 Gy | 93 (81.6 %) |
| BED10 ≥ 100 Gy | 77 (67.5 %) |
| GTV volume (cc), median (range) | 24.4 (1.3–252.1) |
| PTV volume (cc), median (range) | 40.2 (3.6–319.2) |
| Treatment finished | 111 (97.4 %) |
| Prescription dose, mean (95 % CI), Gy | 43.4 (41.6–45.3) |
| No. of fractions, mean (95 % CI) | 4.1 (3.8–4.4) |
| Prescription isodose line, mean (95 % CI) | 79.6 (78.7–80.4) |
| Dmax (Gy), mean (95 % CI) | 54.7 (52.4–57.1) |
| D1 (Gy), mean (95 % CI) | 53.3 (51.0–55.6) |
| D95 (Gy), mean 95 % CI) | 41.2 (39.4–43.0) |
| D99 (Gy), mean 95 % CI) | 34.7 (32.8–36.6) |
| CCI, mean (95 % CI) | 0.81 (0.78–0.84) |
| CCI > 0.90, n (%) | 54 (48 %) |
| CCI > 0.96, n (%) | 16 (14 %) |
Abbreviation: CCI = coverage compromise index, defined as D99/prescription dose. A CCI value < 0.90 indicates coverage compromise, as the SABR-COMET protocol indicated that 99 % of the PTV was to be covered by 90 % of the prescription dose.
*1*16 Gy (n = 1), 1*20 Gy (n = 2), 3*8Gy (n = 2), 3*10 (n = 4), 5*7 Gy (n = 1), 8*7.5 Gy (n = 1).